Two days after the “flameout” of the stock price, the new year demon king Andon Health Co.Ltd(002432) suddenly made a big move.
On the evening of January 19, Andon Health Co.Ltd(002432) released the performance forecast for 2021. It is expected that the net profit attributable to the parent company in 2021 will increase by 271.4% to 395.19% year-on-year, with a profit of 900 million yuan to 1.2 billion yuan.
Compared with the third quarterly report of the company, Andon Health Co.Ltd(002432) the net profit attributable to the parent company in the fourth quarter of 2021 is expected to reach 850 million yuan to 1.15 billion yuan. Data show that the total net profit of the company since its listing is 70 million yuan, that is to say, the money earned in three months far exceeds that in the past 11 years.
As soon as the notice comes out, the stock bar will fry the pot in an instant. Bulls believe that today’s anti package limit, “88.88 yuan is not the end”; Bearers believe that being careful is good for shipping, “falling bags is for safety and a good new year”.
Source: China stock market news
earn more in 3 months than in the past 11 years
According to the performance forecast, Andon Health Co.Ltd(002432) it is expected that the net profit attributable to the parent company will increase by 271.4% to 395.19% year-on-year in 2021, with a profit of RMB 900 million to RMB 1.2 billion; The net profit deducted from non parent company was 850 million yuan to 1.15 billion yuan, with a year-on-year increase of 243.46% to 364.68%.
The company said that its global COVID-19 pneumonia epidemic was affected by the global SARS-CoV-2 pneumonia in 2021. Its sales performance of New Coronavirus (SARS-CoV-2) antigen self testing OTC kit has increased significantly in the US market, which has contributed to a substantial increase in operating performance in 2021.
The company specially emphasizes that it has conducted pre communication with the annual audit accounting firm on this performance forecast, and there is no difference between the two sides.
China Securities Journal · China Securities Taurus reporter noted that the company’s net profit attributable to the parent company in the first three quarters of 2021 is about 50.128 million yuan. Based on this calculation, Andon Health Co.Ltd(002432) it is expected to achieve a net profit attributable to the parent company of 850 million yuan to 1.15 billion yuan in the fourth quarter of 2021. Since the company was listed in 2010, by 2020, the accumulated net profit attributable to the parent company has been about 71.87 million yuan in 11 years.
stand on the air outlet
On the evening of November 7, 2021, Andon Health Co.Ltd(002432) announced that its subsidiary ihealth (hereinafter referred to as the “U.S. subsidiary”) obtained the emergency use authorization (EUA) of the U.S. Food and Drug Administration (FDA), and the company’s share price soared.
Since January 2022, Andon Health Co.Ltd(002432) has quickly signed large orders with a total amount of more than 10 billion yuan within three days. One is the purchase orders and contracts for ihealth kits received by the U.S. subsidiary from New York and Massachusetts, with a cumulative amount of more than 2.1 billion yuan; The other is the ihealth kit product purchase contract signed by the U.S. subsidiary and the U.S. Department of health and human services, with a total amount of about RMB 8.102 billion.
From the lowest 5.8 yuan on October 29 last year to the highest 88.88 yuan on January 18 this year, Andon Health Co.Ltd(002432) the cumulative increase in two and a half months exceeded 14 times.
During this period, I experienced three waves of rising. The first wave was from November 15 to December 1 last year, and received 12 boards for 13 days, the second wave was from December 13 to December 30, and received 11 boards for 14 days, and the third wave was from January 11 to 17 after the opening of the new year.
Andon Health Co.Ltd(002432) is therefore called the “cross year demon king”. Some highly profitable investors even said on the interactive platform that they would donate money to the company to reward and motivate employees.
According to the semi annual report 2021, Andon Health Co.Ltd(002432) has expanded the Internet plus medical management business on the basis of the research and development, production and marketing of medical and health electronics products, and has continuously launched the new products in the new retail platform.
According to the company’s 2020 semi annual report, its operating revenue in the first half of 2020 increased by 222.8% year-on-year to RMB 1.041 billion. In this regard, the company said that it was mainly due to the increase in global sales of epidemic prevention related products such as infrared forehead thermometer during the reporting period.
However, in the first half of 2021, Andon Health Co.Ltd(002432) revenue decreased by 45.32% year-on-year to 569 million yuan, and the net profit attributable to the parent company after deduction was 4.787 million yuan. The company explained that its frontal thermometer, oximeter and other epidemic related products had a significant increase in revenue in the same period of 2020, and the gross profit margin of epidemic materials exported overseas was high. The sales prices of epidemic materials and products in this period follow the market, and the gross profit margin is lower than that in the epidemic period.
It is worth noting that, combined with previous annual reports, the company’s net profit attributable to the parent company after deducting non profits for seven consecutive years from 2013 to 2019 is in a state of loss, and the net cash flow from operating activities is also negative.
Andon Health Co.Ltd(002432) in the newly released 2021 performance forecast, it is suggested that its 2021 operating performance mainly depends on covid-19 testing reagent. Whether the future performance can continue to maintain rapid growth depends mainly on the progress of epidemic prevention and control in the United States, the selection of covid-19 testing products in the United States, the company’s product market competitiveness and channel sales ability, and the future development of conventional business, With great uncertainty.
rush to raise hot money in Lhasa business department
According to the data of China stock market news, in the past three months, the four Lhasa business departments of China stock market news Securities Co., Ltd. have ranked among the top four seats in the sales statistics of Andon Health Co.Ltd(002432) business departments. The cumulative turnover of the dragon and tiger list has reached 6.357 billion yuan, and the total net purchase amount is about 379 million yuan.
Source: China stock market news
It is noteworthy that the Lhasa Business Department of Dongcai securities has repeatedly been listed as the top five seats with the largest purchase amount by the Andon Health Co.Ltd(002432) trading business department. On a single day, on January 5, January 11 and January 13, 2022, two Lhasa business departments of Dongcai securities entered the top five seats in the purchase amount; On December 31, the Lhasa Business Department of Dongcai securities ranked among the top five seats.
On January 18, Andon Health Co.Ltd(002432) share price closed at the limit and closed at 74.53 yuan / share. After hours dragon and tiger list data show that the main funds fled, but hot money seats in Lhasa are still actively raising.
Among the top five buyers of the day, Dongcai securities Lhasa business department occupied four seats, with a cumulative net purchase of 130 million yuan; On that day, the largest seller, East Asia Qianhai securities Shenzhen Branch, had a net sales volume of nearly 470 million yuan, and the sales of a single seat accounted for 5.83% of the total turnover.
Source: China stock market news
On January 19, Andon Health Co.Ltd(002432) fell sharply again, once falling by the limit in the session, and finally closed down by 5.27%.
